“HumaDerm provided an alternative source to rat tail collagen type I with equivalent performance. My hope is that larger implementation of human-sourced biomaterials in current tissue models will expedite the development of more clinically and physiologically relevant regenerative therapies.” “My research lab was able to seamlessly integrate Humabiologics biomaterials into our tumor organoid research. We were able to complement our in-house biomaterials with a quality human-based ECM product”